Medifocus, Inc. (TSXV: MFS, OTC: MDFZF) is a leader in the treatment of cancer and other tumors with focused microwave energy. The company owns two fully-developed technology platforms for this purpose, which both have extensive intellectual property protection in the U.S. Patent Office and in international markets.
The company's primary platform is its Endo-thermotherapy platform, which is a catheter-basis focused heat technology platform that utilizes natural openings to deliver precise microwave thermotherapy to the afflicted regions within the body.
The second platform is the company's Adaptive Phased Array (APA) Microwave Focusing PLatform, which was invented by MIT and licensed to Medifocus. This platform directs precisely focused microwave energy at a tumor in order to shrink or eradicate it without harming surrounding tissue. The company's APA 1000 Breast Cancer Treatment System, which utilizes this APA technology platform, has received approval from the U.S. FDA and Health Canada to conduct Phase III clinical trials.
The company is also working to treat men with Benign Prostatic Hyperplasia (BPH) with its Prolieve(R) system. The company's big 100,000 treatment milestone is rapidly approaching, and the company has grown its user base from 50 sites to over 350 sites, most of which are private urology offices.
